SIC
KNSA icon

SJS Investment Consulting’s Kiniksa Pharmaceuticals KNSA Stock Holding History

SJS Investment Consulting’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.71K Buy
58
+35
+152% +$1.82K ﹤0.01% 1507
2026
Q1 		$1.11K Buy
23
+10
+77% +$443 ﹤0.01% 1431
2025
Q4 		$537 Sell
13
-24
-65% -$963 ﹤0.01% 1497
2025
Q3 		$1.44K Hold
37
– – ﹤0.01% 910
2025
Q2 		$1.02K Buy
+37
New +$942 ﹤0.01% 828

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

SJS Investment Consulting's KNSA Position: Q2 2026 in Review

SJS Investment Consulting increased its Kiniksa Pharmaceuticals (KNSA) stake by 152% in Q2 2026, buying an estimated $1.82K and bringing the position to 58 shares worth $3.71K. The position accounts for ﹤0.01% of the portfolio, ranked #1507.

SJS Investment Consulting first reported a position in KNSA in Q2 2025 and has held it in 5 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • SJS Investment Consulting held 58 shares of Kiniksa Pharmaceuticals worth $3.71K as of Q2 2026.
  • SJS Investment Consulting bought 35 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.82K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1507 holding.
  • SJS Investment Consulting first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.